Skip to main content
Swing Capital

Vivimed Labs Ltd

NSE: VIVIMEDLAB BSE: 532660Pharma

Vivimed Labs Ltd, established in 1988, is primarily engaged in the Business of Active Pharmaceuticals Ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals and Retail Branded Formulation manufacturing.[1][2]

₹6.31
52W: ₹5.15 — ₹29.4
PE 0 · Book ₹5.5 · +15% vs book
Market Cap₹52.3 Cr
Stock P/E—Price to Earnings
ROCE6.45%Return on Capital
ROE42.6%Return on Equity
Div. Yield0%Face Value ₹2

Strengths

  • +Stock is trading at 1.15 times its book value

Weaknesses

  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of -17.8% over past five years.
  • −Promoter holding is low: 7.57%
  • −Company has a low return on equity of -84.0% over last 3 years.
  • −Contingent liabilities of Rs.183 Cr.
  • −Company might be capitalizing the interest cost
  • −Company has high debtors of 161 days.
  • −Promoter holding has decreased over last 3 years: -13.4%

Shareholding Pattern

Promoters7.57%
FIIs1.64%
DIIs0%
Public90.66%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters20.94%20.94%20.94%20.94%7.76%▼13.27.76%7.76%7.57%▼0.2
FIIs1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%
DIIs0%0%0%0%0%0%0%0%
Public77.3%77.3%77.3%77.3%90.47%▲13.290.47%90.47%90.66%▲0.2

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales30373625223423181912
Expenses36366536233425182023
Operating Profit-51-29-11-10-2-1-1-11
OPM %-18%2%-79%-45%-4%-1%-11%-3%-7%-96%
Net Profit-20-166-15-5-7-4-6-7-17
EPS ₹-2.36-1.950.66-1.82-0.6-0.84-0.53-0.66-0.9-2

AI Insights

Revenue Trend

TTM revenue at ₹71Cr, down 31.7% YoY. OPM at -22%.

Debt Position

Borrowings at ₹375Cr. Debt-to-equity ratio: 12.93x. High leverage — monitor closely.

Capex Cycle

CWIP at ₹17Cr (6% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 0% (+0.00pp change). FIIs: 1.64% (+0.00pp change). Promoters hold 7.57%.

Margin & Efficiency

ROCE declining from 10% (Mar 2014) to -6% (Mar 2025). Working capital days: -513.

Recent Announcements